Are Medical Stocks Lagging McKesson (MCK) This Year?
Werte in diesem Artikel
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has McKesson (MCK) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.McKesson is a member of our Medical group, which includes 983 different companies and currently sits at #8 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. McKesson is currently sporting a Zacks Rank of #2 (Buy).The Zacks Consensus Estimate for MCK's full-year earnings has moved 1.8% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.Based on the latest available data, MCK has gained about 23.9% so far this year. Meanwhile, stocks in the Medical group have lost about 3.5% on average. As we can see, McKesson is performing better than its sector in the calendar year.Another Medical stock, which has outperformed the sector so far this year, is Cencora (COR). The stock has returned 27.4% year-to-date.Over the past three months, Cencora's consensus EPS estimate for the current year has increased 2.5%. The stock currently has a Zacks Rank #2 (Buy).To break things down more, McKesson belongs to the Medical - Dental Supplies industry, a group that includes 14 individual companies and currently sits at #30 in the Zacks Industry Rank. This group has gained an average of 0.8% so far this year, so MCK is performing better in this area. In contrast, Cencora falls under the Medical Services industry. Currently, this industry has 58 stocks and is ranked #89. Since the beginning of the year, the industry has moved -6.3%.Investors with an interest in Medical stocks should continue to track McKesson and Cencora. These stocks will be looking to continue their solid performance.Higher. Faster. Sooner. Buy These Stocks NowA small number of stocks are primed for a breakout, and you have a chance to get in before they take off.At any given time, there are only 220 Zacks Rank #1 Strong Buys. On average, this list more than doubles the S&P 500. We’ve combed through the latest Strong Buys and selected 7 compelling companies likely to jump sooner and climb higher than any other stock you could buy this month.You'll learn everything you need to know about these exciting trades in our brand-new Special Report, 7 Best Stocks for the Next 30 Days.Download the report free now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report McKesson Corporation (MCK): Free Stock Analysis Report Cencora, Inc. (COR): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks
Übrigens: McKesson und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.
Ausgewählte Hebelprodukte auf McKesson
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf McKesson
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Quelle: Zacks
Nachrichten zu McKesson Corp.
Analysen zu McKesson Corp.
Datum | Rating | Analyst | |
---|---|---|---|
05.08.2019 | McKesson Peer Perform | Wolfe Research | |
26.10.2018 | McKesson Equal Weight | Barclays Capital | |
20.07.2018 | McKesson Neutral | Robert W. Baird & Co. Incorporated | |
08.03.2018 | McKesson Equal Weight | Barclays Capital | |
02.02.2018 | McKesson Neutral | Mizuho |
Datum | Rating | Analyst | |
---|---|---|---|
23.01.2018 | McKesson Buy | Needham & Company, LLC | |
04.12.2017 | McKesson Buy | Deutsche Bank AG | |
01.11.2017 | McKesson Buy | Needham & Company, LLC | |
25.10.2017 | McKesson Buy | Needham & Company, LLC | |
19.09.2017 | McKesson Outperform | Robert W. Baird & Co. Incorporated |
Datum | Rating | Analyst | |
---|---|---|---|
05.08.2019 | McKesson Peer Perform | Wolfe Research | |
26.10.2018 | McKesson Equal Weight | Barclays Capital | |
20.07.2018 | McKesson Neutral | Robert W. Baird & Co. Incorporated | |
08.03.2018 | McKesson Equal Weight | Barclays Capital | |
02.02.2018 | McKesson Neutral | Mizuho |
Datum | Rating | Analyst | |
---|---|---|---|
Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar. Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für McKesson Corp. nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen